Close Side Menu

Staff Access

PHCC launches COVID-19 Vaccination Hotline Number

05 Jan 2021

Hotline

PHCC have activated a dedicated hotline number 402 77077 to enable those aged 65 years and above to book, cancel or reschedule pre-booked vaccination appointments.  The dedicated line is currently available from 7am to 11pm.

This number will be available to the elderly priority group only at this stage.
 
The Ministry of Public Health announced that it has lowered the age threshold for COVID-19 vaccine eligibility to 65 years of age. The amendment sees the age threshold reduced from 70 years of age and means the following three.

Vaccinations at health centers will continue to be given to people with pre-arranged appointments that fall under the priority groups: 

1) People aged 65 years of age and above;
2) People with severe chronic conditions;
3) Healthcare workers with repeated exposure to COVID-19.

Dr Mariam Abdul Malik, managing director of PHCC commented “To ensure that we are further prioritizing those mostly at risk of severe complications from COVD-19 we have now activated a dedicated hotline number. This dedicated number will improve accessibility for our clients and encourage uptake of the vaccine by providing further flexibility on appointment booking.”

Members of the community who are eligible for the vaccine will continue to be contacted through phone/SMS by the PHCC team to invite them to attend an appointment at one of the ten designated health centers.

The 10 designated PHCC Health Centers are Al Wajbah, Leabaib, Al Ruwais, Umm Salal, Rawdat Al Khail, Al Thumama, Muaither and recently added Al Khor, Qatar University and Al Waab.

The vaccine will be offered more widely throughout the year. MOPH are working with the pharmaceutical companies to ensure the next shipment of vaccines arrives in Qatar as early as possible in 2021 and everyone who needs to be vaccinated will be able to do so throughout the year.

For more information on the COVD-19 vaccine, please visit:
https://covid19.moph.gov.qa/EN/Covid19-Vaccine/Pages/default.aspx